Dual PPARα/γ agonist aleglitazar confers stroke protection in a model of mild focal brain ischemia in mice
Open Access
- 30 May 2019
- journal article
- research article
- Published by Springer Science and Business Media LLC in Journal of Molecular Medicine
- Vol. 97 (8), 1127-1138
- https://doi.org/10.1007/s00109-019-01801-0
Abstract
Peroxisome proliferator-activated receptors (PPARs) control the expression of genes involved in glucose homeostasis, lipid metabolism, inflammation, and cell differentiation. Here, we analyzed the effects of aleglitazar, a dual PPARα and PPARγ agonist with balanced affinity for either subtype, on subacute stroke outcome. Healthy young adult mice were subjected to transient 30 min middle cerebral artery occlusion (MCAo)/reperfusion. Daily treatment with aleglitazar was begun on the day of MCAo and continued until sacrifice. Blood glucose measurements and lipid profile did not differ between mice receiving aleglitazar and mice receiving vehicle after MCAo. Aleglitazar reduced the size of the ischemic lesion as assessed using NeuN immunohistochemistry on day 7. Sensorimotor performance on the rotarod was impaired during the first week after MCAo, an effect that was significantly attenuated by treatment with aleglitazar. Smaller lesion volume in mice treated with aleglitazar was accompanied by a decrease in mRNA transcription of IL-1β, Vcam-1, and Icam-1, suggesting that reduced proinflammatory signaling and reduced vascular inflammation in the ischemic hemisphere contribute to the beneficial effects of aleglitazar during the first week after stroke. Further experiments in primary murine microglia confirmed that aleglitazar reduces key aspects of microglia activation including NO production, release of proinflammatory cytokines, migration, and phagocytosis. In aggregate, a brief course of PPARα/γ agonist aleglitazar initiated post-event affords stroke protection and functional recovery in a model of mild brain ischemia. Our data underscores the theme of delayed injury processes such as neuroinflammation as promising therapeutic targets in stroke.Keywords
Funding Information
- DFG (Exc257, KR 2956/4-1, GE 2576/2-1)
- Bundesministerium für Bildung und Forschung (CSB)
- DZNE (n.a.)
- DZHK (n.a.)
- Corona Foundation (n.a.)
- F. Hoffmann-La Roche (n.a.)
This publication has 55 references indexed in Scilit:
- Evaluation of the dual peroxisome proliferator–activated receptor α/γ agonist aleglitazar to reduce cardiovascular events in patients with acute coronary syndrome and type 2 diabetes mellitus: Rationale and design of the AleCardio trialAmerican Heart Journal, 2013
- Central and haematopoietic interleukin-1 both contribute to ischaemic brain injury in miceDisease Models & Mechanisms, 2013
- Comparative Transcriptional Network Modeling of Three PPAR-α/γ Co-Agonists Reveals Distinct Metabolic Gene Signatures in Primary Human HepatocytesPLOS ONE, 2012
- Comparative Molecular Profiling of the PPARα/γ Activator Aleglitazar: PPAR Selectivity, Activity and Interaction with CofactorsChemMedChem, 2012
- Essential role of interleukin-6 in post-stroke angiogenesisBrain, 2012
- Peroxisome proliferator-activated receptor γ promotes neuroprotection by modulating cyclic D1 expression after focal cerebral ischemiaCanadian Journal of Physiology and Pharmacology, 2010
- Improving Bioscience Research Reporting: The ARRIVE Guidelines for Reporting Animal ResearchPLoS Biology, 2010
- Fenofibrate Improves Cerebral Blood Flow after Middle Cerebral Artery Occlusion in MiceJournal of Cerebral Blood Flow & Metabolism, 2009
- Neuronal PPARγ Deficiency Increases Susceptibility to Brain Damage after Cerebral IschemiaJournal of Neuroscience, 2009
- Angiopoietin1/TIE2 and VEGF/FLK1 Induced by MSC Treatment Amplifies Angiogenesis and Vascular Stabilization after StrokeJournal of Cerebral Blood Flow & Metabolism, 2007